DeepMed Research

Suzhou Connect Biopharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

First Posted Date: 2023-06-26

Last Posted Date: 2023-10-31

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 324

Registration Number: NCT05917782

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Phase 2

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: CBP-201

First Posted Date: 2023-06-15

Last Posted Date: 2023-12-11

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 360

Registration Number: NCT05905133

Locations: 🇨🇳
Connect Investigative Site 03, Guangzhou, Guangdong, China
🇨🇳
Connect Investigative Site 34, Nanjing, Jiangsu, China
🇨🇳
Connect Investigative Site 41, Beijing, Beijing, China

and more 35 locations

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Phase 3

Withdrawn

Conditions: Atopic Dermatitis

Interventions: Drug: CBP-201
Drug: Placebo

First Posted Date: 2022-11-14

Last Posted Date: 2023-03-21

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Registration Number: NCT05614817

A Study On Human Mass Balance And Biotransformation

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: CBP-307

First Posted Date: 2021-09-10

Last Posted Date: 2022-04-05

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 6

Registration Number: NCT05040113

Locations: 🇨🇳
Connect Investigative Site, Suzhou, Jiangsu, China

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Phase 2

Completed

Conditions: Moderate-to-severe Atopic Dermatitis

Interventions: Drug: CBP-201
Drug: Placebo

First Posted Date: 2021-08-23

Last Posted Date: 2024-05-01

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 330

Registration Number: NCT05017480

Locations: 🇨🇳
Connect Investigative Site 33, Hefei, Anhui, China
🇨🇳
Connect Investigative Site 32, Shijiazhuang, Hebei, China
🇨🇳
Connect Investigative Site 47, Beijing, Beijing, China

and more 45 locations

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Phase 2

Terminated

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: CBP-201
Drug: Placebo

First Posted Date: 2021-03-05

Last Posted Date: 2023-10-17

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 40

Registration Number: NCT04783389

Locations: 🇺🇸
Connect Investigative Site 104, Dallas, Texas, United States
🇺🇸
Connect Investigative Site 123, Cincinnati, Ohio, United States
🇺🇸
Connect Investigative Site 120, Houston, Texas, United States

and more 65 locations

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Phase 2

Completed

Conditions: Moderate to Severe Persistent Asthma

Interventions: Drug: Placebo
Drug: CBP-201

First Posted Date: 2021-02-26

Last Posted Date: 2024-03-29

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 322

Registration Number: NCT04773678

Locations: 🇺🇸
Connect Investigative Site 123, Winter Park, Florida, United States
🇺🇸
Connect Investigative Site 147, Toledo, Ohio, United States
🇨🇳
Connect Investigative Site 217, Ningbo, Zhejiang, China

and more 73 locations

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Phase 2

Completed

Conditions: Moderate to Severe Ulcerative Colitis

Interventions: Drug: Open-label CBP-307
Drug: Double-Blind 0.2mg CBP-307
Drug: Double-Blind Placebo
Drug: Double-Blind 0.1mg CBP-307

First Posted Date: 2021-01-07

Last Posted Date: 2024-05-06

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 145

Registration Number: NCT04700449

Locations: 🇺🇸
Connect Investigative Site 2314, Hialeah, Florida, United States
🇺🇸
Connect Investigative Site 2320, Kissimmee, Florida, United States
🇨🇳
Connect Investigative Site 2015, Jilin, Changchun, China

and more 63 locations

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Moderate-to-severe Atopic Dermatitis

Interventions: Drug: CBP-201
Drug: placebo

First Posted Date: 2020-06-24

Last Posted Date: 2023-08-01

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 226

Registration Number: NCT04444752

Locations: 🇺🇸
Connect Investigative Site 318, Sherman Oaks, California, United States
🇺🇸
Connect Investigative Site 323, San Luis Obispo, California, United States
🇺🇸
Connect Investigative Site 332, Coral Gables, Florida, United States

and more 56 locations

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Phase 1

Completed

Conditions: Autoimmune Diseases

Interventions: Drug: Placebo
Drug: CBP-307

First Posted Date: 2014-10-31

Last Posted Date: 2016-11-03

Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Target Recruit Count: 64

Registration Number: NCT02280434

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy